Skip to main content
Home > Week in Review > Offerings

Chronological Index of : Financial News

 Current Issue
  • Transcriptic completes venture financing

    Transcriptic raised $13.4 million in a series A-1 round led by Data Collective. New investors Digital Science and WuXi AppTec and existing investors, including AME Cloud Ventures, participated.Transcriptic Inc., Menlo …

    Published on 12/5/2016
  • Xencor completes follow-on

    Xencor raised $110 million through the sale of 4.6 million shares at $24 in a follow-on underwritten by Leerink Partners, Canaccord and Wedbush.Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif.

    Published on 12/5/2016
  • Arch Venture Partners financial update

    Arch Venture Partners has raised $408.4 million towards its Arch Venture Fund IX L.P., according to an SEC filing. The fund's target is $550 million, up from a planned $400 million in March. According to a separate …

    Published on 12/5/2016
  • V-Bio Ventures financial update

    V-Bio Ventures closed its first life sciences fund at 76 million ($81 million). V-Bio Ventures Fund 1 is designed to fund 15-18 early stage companies developing therapeutics, diagnostics and agricultural products.V-Bio …

    Published on 12/5/2016
  • Clearside Biomedical proposes follow-on

    Clearside proposed to raise $75 million in a follow-on underwritten by JPMorgan, Cowen, Stifel and Wedbush.Clearside Biomedical Inc. (NASDAQ:CLSD), Alpharetta, Ga.

    Published on 12/5/2016
  • Recro proposes follow-on

    Recro Pharma proposed to raise up to $57.5 million in a follow-on underwritten by Piper Jaffray.Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa.

    Published on 12/5/2016
  • Cellectar amends follow-on

    Cellectar amended its follow-on and added Aegis Capital as an underwriter; Ladenburg Thalmann remains an underwriter. The company plans to sell up to $10 million in common stock, plus five-year warrants.Cellectar …

    Published on 11/28/2016
  • Fate completes private placement

    Fate raised $57 million in a private placement through the sale of 2.8 million preferred shares at $13.30 to Redmile Group LLC and 7.2 million shares of common stock at $2.66 to BVF Partners L.P., EcoR1 Capital LLC, …

    Published on 11/28/2016
  • Recursion financial update

    Recursion raised $2.2 million in an additional close of series A round, bringing the total raised to $15.1 million. New investor Felicis Ventures and individual investors participated.Recursion Pharmaceuticals LLC, Salt…

    Published on 11/28/2016
  • RXi amends follow-on

    RXi amended its follow-on and now plans to sell 2 million class A units and 9,600 class B units. The company also added Griffin Securities as an underwriter; Ladenburg Thalmann is also an underwriter. The units comprise…

    Published on 11/21/2016
  • Aclaris completes follow-on

    Aclaris raised $91 million through the sale of 4 million shares at $22.75 in a follow-on underwritten by Jefferies, Leerink Partners, Guggenheim Securities, William Blair and JMP Securities.Aclaris Therapeutics Inc. (…

    Published on 11/21/2016
  • AmpliPhi completes follow-on

    AmpliPhi raised $4 million through the sale of 5.3 million shares at $0.74 and 5.3 million five-year warrants at $0.01 per warrant in a follow-on underwritten by Roth Capital Partners and Griffin Securities. Each …

    Published on 11/21/2016
  • BeiGene completes follow-on

    BeiGene raised $185 million through the sale of 5.8 million ADSs at $32 in a follow-on underwritten by Morgan Stanley, Goldman Sachs, Cowen, Baird and William Blair. Shareholders raised $15 million through the sale of …

    Published on 11/21/2016
  • Biocartis completes private placement

    Biocartis raised 32.7 million ($35.1 million) through the sale of 4.1 million shares at 8.05 in a private placement underwritten by Degroof Petercam, KBC Securities and Kempen & Co.Biocartis Group N.V. (Euronext:…

    Published on 11/21/2016
  • BioPorto completes private placement

    BioPorto raised DKK21.8 million ($3.1 million) through the sale of 12.9 million shares at DKK1.69 in a private placement to existing investors and institutional investors.BioPorto Diagnostics A/S (CSE:BIOPOR), Gentofte,…

    Published on 11/21/2016
  • Flexion Therapeutics completes follow-on

    Flexion raised $64.8 million through the sale of 3.6 million shares at $18 in a follow-on underwritten by Wells Fargo, RBC Capital Markets and BMO Capital Markets.Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, …

    Published on 11/21/2016
  • Glycomine completes venture financing

    Glycomine raised $12 million in a series A round led by Sanderling Ventures. Chiesi Ventures and individual investors also participated.Glycomine Inc., San Francisco, Calif.

    Published on 11/21/2016
  • Immune Pharmaceuticals completes private placement of convertible notes

    Immune Pharmaceuticals raised $1 million in a convertible note from an existing investor. The company may raise up to an additional $10 million from the investor.Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New …

    Published on 11/21/2016
  • Immune Therapeutics completes debt financing

    Immune raised $750,000 in one-year promissory notes that bear 2% interest from an existing investor.Immune Therapeutics Inc. (OTCBB:IMUN), Orlando, Fla.

    Published on 11/21/2016
  • Invitae completes follow-on

    Invitae raised $44 million through the sale of 7.3 million shares at $6 in a follow-on underwritten by JPMorgan and Cowen.Invitae Corp. (NYSE:NVTA), San Francisco, Calif.

    Published on 11/21/2016
  • Lantheus completes follow-on

    Lantheus raised $9 million through the sale of 9 million shares at $1 in a follow-on underwritten by Credit Suisse. Lantheus Holdings Inc. (NASDAQ:LNTH), North Billerica, Mass.

    Published on 11/21/2016
  • Magenta Therapeutics completes venture financing

    Magenta raised $48.5 million in a series A round led by Third Rock Ventures and Atlas Venture. GV, Access Industries and Partners Innovation Fund also participated.Magenta Therapeutics, Cambridge, Mass.

    Published on 11/21/2016
  • MorphoSys completes private placement

    MorphoSys raised 115.4 million ($123.8 million) through the sale of 2.6 million shares at 44 in a private placement to institutional investors. Deutsche Bank and JPMorgan were underwriters.MorphoSys AG (Xetra:MOR; Pink:…

    Published on 11/21/2016
  • Motif Bio completes follow-on and concurrent private placement

    Motif raised $17 million through the sale of 2.4 million ADSs at $6.98 in a follow-on on NASDAQ underwritten by H.C. Wainwright. For each ADS sold, investors received a five-year warrant to purchase 0.5 ADSs, with each …

    Published on 11/21/2016
  • Neurotrope completes private placement of common stock and warrants

    Neurotrope raised $20.2 million through the sale of 100.9 million shares at $0.20 in a private placement to new and existing investors. Investors also received five-year warrants to purchase up to 100.9 million shares …

    Published on 11/21/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993